Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common chemo drug boost the benefits of palliative radiation for advanced cancer?

NCT ID NCT03637335

Disease control Sponsor: Institut Cancerologie de l'Ouest Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether adding the chemotherapy drug carboplatin to standard palliative radiotherapy helps control tumor growth and reduce pain better than radiotherapy alone. The study includes adults with advanced lung or head and neck cancer who need palliative radiation. Participants receive either radiotherapy plus carboplatin or radiotherapy plus a placebo, and researchers track how long the treated tumors stay under control, pain levels, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
carboplatin
What this could lead to
If it works, this approach could improve pain control and quality of life for people with advanced cancer, and possibly extend survival.
What could go wrong
This is a small early-phase trial, so results may not be conclusive. Adding chemotherapy to radiotherapy can increase side effects like low blood counts and fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

26 people

The number who actually took part.

Started

Aug 2015

Finished

May 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with locally advanced or metastatic bronchial or head and neck cancer * Patient require palliative radiotherapy * Age ≥ 18 years * PS ≤ 2 * Obtaining the signed written consent of the patient * Patient affiliated to a social security scheme Exclusion Criteria: * Other chemotherapy or targeted therapy * Prior radiation * Patients with thrombopenia \< 100 000 * Patients with neutropenia \< 2000 * Patients with renal clearance \< 20 mL/min * Known hypersensitivity to platinum salt * Treatment with phenytoin or fosphenytoin * In previous three months, a vaccination against yellow fever, live vaccin or live attenuated vaccine * Unchecked diabetes * hemorrhagic tumor * Refusal of participation or inability to issue informed consent * Person deprived of liberty or adult under guardianship * Minor patients, pregnant or lactating women * Participation in other interventional study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bronchial cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bronchus cancer head and neck cancer Head and Neck Neoplasms lung cancer lung neoplasm metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Head and neck cancer Lung cancer Metastatic cancer

Contacts and locations

Locations

  • Fabrice Denis

    Le Mans, 72000, France

  • Institut de Cancérologie de l'Ouest

    Nantes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.